Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Publication | Closed Access

DOI

609

Citations

References

2023

Year

Kohei Shitara, Florian Lordick, Yung‐Jue Bang, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Eric Van Cutsem, Rui‐Hua Xu, Giuseppe Aprile, Jianming Xu,

The Lancet

OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaGastroenterologyPathologyMetastatic GastricCancer TreatmentMedicineRadiation OncologyCancer ResearchMolecular Oncology